TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSXV:ATE) is pleased to announce the submission of a Clinical Trial Application (“CTA”) to Health Canada for its lead drug, ATB-346. The CTA proposes the initiation of a clinical study entitled “A Double-Blind, Placebo-Controlled, Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single/Multiple Ascending Doses of ATB-346 Orally Administered in Healthy Male and Female Subjects.” The submission represents a significant milestone on a well-defined pathway for the development of ATB-346.
Help employers find you! Check out all the jobs and post your resume.
